

EQA round: RF1/24 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 15.3.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
Set 1															
(277) anti-CCP IgG	[kU/L]				13								0		
Sample A1													0		
Other					13	2							0		
							4x 1, 3x 60, 1x 66, 2x 135, 1x 140, 1x 148, 1x 179								
Sample B1													0		
Other					13	2							0		
							4x 1, 3x 60, 1x 66, 2x 135, 1x 140, 1x 148, 1x 179								
(282) anti-MCV	[kU/L]				4								0		
Sample A1													0		
Other					4	0							0		
							4x 135								
Sample B1													0		
Other					4	0							0		
							4x 135								
(231) Rheumat. fac. (scr)	[kU/L]				17								15	14	93
Sample A1		7,63	4	52	17								15	14	93
(58) Beckman Coulter (AU)		6,1	1,6	27	6	0	CVPG	6,7	1,4	66%	2,27	11,2	6		
(60) Roche		9,4	2,1	22	5	1	CVPG	9,44	0,42	66%	3,2	15,7	5		
Other					6	0							4		
							2x 1, 1x 148, 1x 162, 1x 178, 1x 179								
Sample B1		91,3	40	44	17								15	14	93
(58) Beckman Coulter (AU)		72,9	3,1	4,3	6	0	CVPG	71	1,6	33%	47,5	94,5	6		
(60) Roche		68,2	3,5	5,1	5	1	CVPG	66	0,72	33%	44,2	87,8	5		
Other					6	0							4		
							2x 1, 1x 148, 1x 162, 1x 178, 1x 179								
(233) Rheumat. factor IgG	[kU/L]				1								0		
Sample A1													0		
Other					1	0							0		
							1x 58								
Sample B1													0		
Other					1	0							0		
							1x 58								
Set 2															
(237) anti-streptolysin O (ASLO)	[kU/L]				20								18	18	100
Sample A2		165	15	8,8	20								18	18	100
(58) Beckman Coulter (AU)		163	3	1,8	9	0	CVPG	165	2,5	20%	132	198	9		
(60) Roche		172	20	12	6	0	CVPG	175	4,1	20%	140	210	6		
Other					5	0							3		
							2x 1, 1x 162, 2x 178								
Sample B2		611	71	12	20								18	18	100
(58) Beckman Coulter (AU)		649	8,2	1,3	9	0	CVPG	650	11	20%	520	780	9		
(60) Roche		584	13	2,3	6	0	CVPG	584	11	20%	467	701	6		
Other					5	0							3		
							2x 1, 1x 162, 2x 178								